Bedford, Massachusetts-based Instylla said the Tembo system is a bioresorbable embolization agent with particles designed for embolization of hypervascular tumors and blood vessels to occlude blood flow in the peripheral vasculature. Those irregularly shaped, dry gelatin particles range in size between 85 and 255 micrometers.

“We plan to collaborate with leading experts in interventional radiology to maximize the clinical benefits of the Tembo Embolic System,” Instylla CEO Amar Sawhney said in a news release. “While our primary focus continues to be the completion of the PMA process for our flagship product, Embrace Hydrogel Embolic System, we pride ourselves on providing novel resorbable embolic agents to interventional radiologists specifically designed for new and existing embolotherapies.”